Please login to the form below

Not currently logged in
Email:
Password:

Ipsen’s chief scientific officer steps down

Dr Claude Bertrand will be replaced ad interim by Alexandre Lebeaut

Ipsen Dr Claude BertrandIpsen's executive vice president of research and development and chief scientific officer Dr Claude Bertrand has stepped down from his post.

He will be replaced by Dr Alexandre Lebeaut as interim head of research and development while the firm searches for a permanent successor.

Dr Bertrand joined the French pharmaceutical firm in 2009, having moved from AstraZeneca where he most recently served as global vice president for launched and established brands.

Prior to this, Dr Bertrand held director-level and senior research positions at Novartis, Pfizer and Roche.

David Meek, chief executive officer of Ipsen, said: “On behalf of the company, I would like to thank Dr Bertrand for his significant contribution to leading the R&D organization during the past seven years.

“We wish him well as he moves on to pursue a new opportunity.”

He added: “We are fortunate to have an experienced and successful R&D leader like Dr Lebeaut to step up and lead the R&D team.”

12th January 2017

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

What are you doing, Dave?
Artificial Intelligence (AI) is invading all areas of healthcare. Is it our saviour or our nemesis?...
Fake News is Bad for your Health
Ill informed patients make poor health decisions...
Secrets of Pharma Advertising
If the goal of branding is to be different, why do so many Pharma brand ads look the same?...

Infographics